Q4FY17 Results: Dr Lal PathLabs Ltd
Amir Shaikh / 12 May 2017
Dr Lal PathLabs Ltd. reported its results for the quarter ended March 31, 2017 today.
Dr Lal PathLabs Ltd. reported its results for the quarter ended March 31, 2017 today.
The company's total sales for Q4FY17 came in at Rs 219.9 crore, which represents a 5.99 per cent sequential increase and 11.22 per cent YoY increase.
Its operating profit (EBIT) for the quarter amounted to Rs. 41.43 crore and its EBIT margin stood at 18.84 per cent.
The company reported PAT of Rs 30.99 crore, which represents a sequential QoQ increase of 0.06 per cent and a YoY decline of 10.02 per cent.
During FY16-17, the company reported 15.3 per cent YoY increase in revenue to Rs. 912 crore and 12.8 per cent in EBITDA to Rs. 237 crore. The company posted bottomline growth of 16.6 per cent YoY to Rs 154 crore
The stock opened at Rs 963 and closed at Rs 900, a fall of 6.60%.
Dr. Lal PathLabs Limited is engaged in providing diagnostic and related healthcare tests and services. The company is engaged in the business of running laboratories for carrying out pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, other pathological and radiological investigations.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.